|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NDUFB10 |
Gene summary for NDUFB10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NDUFB10 | Gene ID | 4716 |
| Gene name | NADH:ubiquinone oxidoreductase subunit B10 | |
| Gene Alias | MC1DN35 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | A8K761 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4716 | NDUFB10 | GSM4909286 | Human | Breast | IDC | 1.71e-03 | -2.50e-01 | 0.1081 |
| 4716 | NDUFB10 | GSM4909287 | Human | Breast | IDC | 2.33e-08 | 4.03e-01 | 0.2057 |
| 4716 | NDUFB10 | GSM4909291 | Human | Breast | IDC | 2.09e-03 | 3.44e-01 | 0.1753 |
| 4716 | NDUFB10 | GSM4909293 | Human | Breast | IDC | 1.03e-12 | 4.15e-01 | 0.1581 |
| 4716 | NDUFB10 | GSM4909294 | Human | Breast | IDC | 5.45e-16 | 3.29e-01 | 0.2022 |
| 4716 | NDUFB10 | GSM4909296 | Human | Breast | IDC | 4.45e-12 | 1.08e-01 | 0.1524 |
| 4716 | NDUFB10 | GSM4909297 | Human | Breast | IDC | 1.08e-16 | 9.37e-03 | 0.1517 |
| 4716 | NDUFB10 | GSM4909298 | Human | Breast | IDC | 6.65e-10 | 4.06e-01 | 0.1551 |
| 4716 | NDUFB10 | GSM4909301 | Human | Breast | IDC | 2.60e-10 | 3.04e-01 | 0.1577 |
| 4716 | NDUFB10 | GSM4909302 | Human | Breast | IDC | 2.67e-03 | 2.35e-01 | 0.1545 |
| 4716 | NDUFB10 | GSM4909304 | Human | Breast | IDC | 7.28e-28 | 5.62e-01 | 0.1636 |
| 4716 | NDUFB10 | GSM4909305 | Human | Breast | IDC | 7.77e-03 | 3.05e-01 | 0.0436 |
| 4716 | NDUFB10 | GSM4909306 | Human | Breast | IDC | 3.90e-40 | 7.09e-01 | 0.1564 |
| 4716 | NDUFB10 | GSM4909307 | Human | Breast | IDC | 5.59e-15 | 4.24e-01 | 0.1569 |
| 4716 | NDUFB10 | GSM4909308 | Human | Breast | IDC | 4.76e-19 | 5.26e-01 | 0.158 |
| 4716 | NDUFB10 | GSM4909311 | Human | Breast | IDC | 7.51e-42 | -1.48e-01 | 0.1534 |
| 4716 | NDUFB10 | GSM4909312 | Human | Breast | IDC | 4.61e-10 | -2.82e-02 | 0.1552 |
| 4716 | NDUFB10 | GSM4909313 | Human | Breast | IDC | 1.24e-02 | 1.66e-01 | 0.0391 |
| 4716 | NDUFB10 | GSM4909317 | Human | Breast | IDC | 4.64e-16 | 5.20e-01 | 0.1355 |
| 4716 | NDUFB10 | GSM4909318 | Human | Breast | IDC | 1.18e-13 | 6.45e-01 | 0.2031 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
| GO:00061199 | Breast | Precancer | oxidative phosphorylation | 53/1080 | 141/18723 | 1.15e-29 | 2.04e-26 | 53 |
| GO:00090608 | Breast | Precancer | aerobic respiration | 58/1080 | 189/18723 | 5.69e-27 | 7.62e-24 | 58 |
| GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
| GO:00453338 | Breast | Precancer | cellular respiration | 59/1080 | 230/18723 | 5.97e-23 | 5.32e-20 | 59 |
| GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
| GO:00196468 | Breast | Precancer | aerobic electron transport chain | 34/1080 | 87/18723 | 3.95e-20 | 2.64e-17 | 34 |
| GO:00427738 | Breast | Precancer | ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
| GO:00427758 | Breast | Precancer | mitochondrial ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
| GO:00229048 | Breast | Precancer | respiratory electron transport chain | 35/1080 | 114/18723 | 8.51e-17 | 3.26e-14 | 35 |
| GO:00229008 | Breast | Precancer | electron transport chain | 42/1080 | 175/18723 | 1.37e-15 | 4.59e-13 | 42 |
| GO:00061208 | Breast | Precancer | mitochondrial electron transport, NADH to ubiquinone | 19/1080 | 51/18723 | 2.05e-11 | 2.49e-09 | 19 |
| GO:00102578 | Breast | Precancer | NADH dehydrogenase complex assembly | 19/1080 | 57/18723 | 1.93e-10 | 1.92e-08 | 19 |
| GO:00329818 | Breast | Precancer | mitochondrial respiratory chain complex I assembly | 19/1080 | 57/18723 | 1.93e-10 | 1.92e-08 | 19 |
| GO:00331088 | Breast | Precancer | mitochondrial respiratory chain complex assembly | 24/1080 | 93/18723 | 3.39e-10 | 3.16e-08 | 24 |
| GO:004603414 | Breast | IDC | ATP metabolic process | 85/1434 | 277/18723 | 6.42e-30 | 1.82e-26 | 85 |
| GO:000611913 | Breast | IDC | oxidative phosphorylation | 56/1434 | 141/18723 | 1.87e-26 | 3.53e-23 | 56 |
| GO:000906013 | Breast | IDC | aerobic respiration | 61/1434 | 189/18723 | 4.42e-23 | 6.27e-20 | 61 |
| GO:000609113 | Breast | IDC | generation of precursor metabolites and energy | 103/1434 | 490/18723 | 1.53e-21 | 1.74e-18 | 103 |
| GO:004533313 | Breast | IDC | cellular respiration | 62/1434 | 230/18723 | 5.98e-19 | 4.25e-16 | 62 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa0501232 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
| hsa0501632 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
| hsa0501432 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
| hsa0520852 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
| hsa0493252 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
| hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
| hsa0471432 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
| hsa0541532 | Liver | HCC | Diabetic cardiomyopathy | 151/4020 | 203/8465 | 2.72e-15 | 1.01e-13 | 5.63e-14 | 151 |
| hsa0501032 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
| hsa0019032 | Liver | HCC | Oxidative phosphorylation | 103/4020 | 134/8465 | 2.39e-12 | 5.01e-11 | 2.79e-11 | 103 |
| hsa0502232 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa0501242 | Liver | Cyst | Parkinson disease | 46/339 | 266/8465 | 1.10e-17 | 1.06e-15 | 8.75e-16 | 46 |
| hsa0520862 | Liver | Cyst | Chemical carcinogenesis - reactive oxygen species | 40/339 | 223/8465 | 4.80e-16 | 3.45e-14 | 2.85e-14 | 40 |
| hsa0019042 | Liver | Cyst | Oxidative phosphorylation | 30/339 | 134/8465 | 5.65e-15 | 3.25e-13 | 2.69e-13 | 30 |
| hsa0493262 | Liver | Cyst | Non-alcoholic fatty liver disease | 32/339 | 155/8465 | 7.91e-15 | 3.80e-13 | 3.14e-13 | 32 |
| hsa0502042 | Liver | Cyst | Prion disease | 42/339 | 273/8465 | 2.36e-14 | 9.70e-13 | 8.01e-13 | 42 |
| hsa0541542 | Liver | Cyst | Diabetic cardiomyopathy | 34/339 | 203/8465 | 6.93e-13 | 2.50e-11 | 2.06e-11 | 34 |
| hsa0501642 | Liver | Cyst | Huntington disease | 42/339 | 306/8465 | 1.27e-12 | 4.06e-11 | 3.35e-11 | 42 |
| hsa0501442 | Liver | Cyst | Amyotrophic lateral sclerosis | 46/339 | 364/8465 | 1.99e-12 | 5.74e-11 | 4.75e-11 | 46 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NDUFB10 | SNV | Missense_Mutation | novel | c.94N>A | p.Asp32Asn | p.D32N | O96000 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-BH-A42V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NDUFB10 | SNV | Missense_Mutation | c.385G>A | p.Val129Met | p.V129M | O96000 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| NDUFB10 | SNV | Missense_Mutation | c.81G>A | p.Met27Ile | p.M27I | O96000 | protein_coding | tolerated(0.44) | benign(0) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| NDUFB10 | deletion | Frame_Shift_Del | c.84delG | p.Met28IlefsTer12 | p.M28Ifs*12 | O96000 | protein_coding | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |||
| NDUFB10 | SNV | Missense_Mutation | c.461N>A | p.Arg154Lys | p.R154K | O96000 | protein_coding | tolerated(1) | benign(0) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NDUFB10 | SNV | Missense_Mutation | novel | c.163N>C | p.Tyr55His | p.Y55H | O96000 | protein_coding | tolerated(0.09) | possibly_damaging(0.83) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NDUFB10 | SNV | Missense_Mutation | c.295N>G | p.Ile99Val | p.I99V | O96000 | protein_coding | tolerated(0.24) | benign(0.062) | TCGA-CK-6748-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| NDUFB10 | SNV | Missense_Mutation | c.211N>C | p.Cys71Arg | p.C71R | O96000 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NDUFB10 | SNV | Missense_Mutation | rs149920175 | c.191G>A | p.Arg64His | p.R64H | O96000 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NDUFB10 | SNV | Missense_Mutation | rs140580390 | c.277G>A | p.Asp93Asn | p.D93N | O96000 | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4716 | NDUFB10 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
| 4716 | NDUFB10 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE | |
| 4716 | NDUFB10 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |